Related Experiment Videos
Isolated profound thrombocytopenia associated with clopidogrel.
F Elmi1, T Peacock, J Schiavone
1Geisinger Medical Center, Cardiology MC 21-60, 100 N. Academy Avenue, Danville, PA 17822, USA. felmil@geisinger.edu
The Journal of Invasive Cardiology
|October 7, 2000
Summary
Clopidogrel, an antiplatelet drug, can cause thrombocytopenia, a low platelet count. This case highlights prompt recovery after drug cessation and treatment, distinct from thrombotic thrombocytopenic purpura.
Area of Science:
- Pharmacology
- Hematology
- Drug Safety
Background:
- Clopidogrel is a widely used oral antiplatelet agent, favored over ticlopidine due to its improved safety and dosing.
- The CAPRIE study demonstrated clopidogrel's favorable safety profile compared to aspirin in preventing ischemic events.
- Post-marketing surveillance identified rare cases of clopidogrel-associated thrombotic thrombocytopenic purpura (TTP).
Observation:
- This report details a patient experiencing isolated profound thrombocytopenia following clopidogrel administration.
- The patient did not exhibit other clinical or laboratory signs consistent with thrombotic thrombocytopenic purpura (TTP).
Findings:
- Discontinuation of clopidogrel led to a rapid and complete recovery of platelet counts.
- Intravenous immunoglobulin therapy was administered as part of the treatment regimen.
Implications:
- Clopidogrel can induce severe thrombocytopenia, which is reversible upon drug withdrawal.
- Distinguishing clopidogrel-induced thrombocytopenia from TTP is crucial for appropriate patient management.
- This case underscores the importance of monitoring platelet counts in patients receiving clopidogrel, especially those presenting with unexplained bleeding or bruising.